Eur Rev Med Pharmacol Sci 2020; 24 (4): 2151-2161
DOI: 10.26355/eurrev_202002_20395

Sesame lignans reduce LDL oxidative susceptibility by downregulating the platelet-activating factor acetylhydrolase

Y. Nakamura, H. Okumura, Y. Ono, Y. Kitagawa, T. Rogi, H. Shibata

Institute for Health Care Science, Suntory Wellness Limited, Kyoto, Japan. Yoshiko_Toyoda@suntory.co.jp


OBJECTIVE: Low-density lipoprotein (LDL) oxidative susceptibility is recognized as a risk factor for atherosclerosis. We previously reported that the ingestion of a supplement containing sesame lignans (sesamin/episesamin) for 4 weeks reduced LDL oxidative susceptibility in humans.

MATERIALS AND METHODS: To elucidate the mechanisms underlying this observation, 12-week-old New Zealand White rabbits were fed a fat/cholesterol-enriched diet (100 g/day) for 6 weeks followed by oral administration of vehicle (control) or sesame lignans (50 mg/kg) for 4 weeks with the fat/cholesterol-enriched diet.

RESULTS: The results showed that the ingestion of sesame lignans prolonged LDL oxidation lag time, regardless of the existence of the anti-oxidative catechol metabolite of sesamin/episesamin in LDL. Plasma platelet-activating factor acetylhydrolase (PAF-AH) activity was significantly reduced by sesame lignans. The prolongation of LDL oxidation lag time was abolished by the addition of a PAF-AH inhibitor. The expression level of pro-inflammatory cytokines and macrophage infiltration observed in the liver following the feeding of the fat/cholesterol-enriched diet were also significantly reduced by sesame lignans.

CONCLUSIONS: These results indicate that sesame lignans reduce LDL oxidative susceptibility by downregulating plasma PAF-AH activity via the reduction of inflammation in the liver induced by fat/cholesterol-enriched diets.

Free PDF Download

To cite this article

Y. Nakamura, H. Okumura, Y. Ono, Y. Kitagawa, T. Rogi, H. Shibata
Sesame lignans reduce LDL oxidative susceptibility by downregulating the platelet-activating factor acetylhydrolase

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 4
Pages: 2151-2161
DOI: 10.26355/eurrev_202002_20395